Values as of: 2024-09-18
COMMON STOCK | Biotechnology |
Last Closing
USD 28.21Change
-0.03 (-0.11)%Market Cap
USD 16.45BVolume
1.21MAnalyst Target
USD 52.29Verdict
Verdict
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Company Website : https://www.royaltypharma.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| REGN | Regeneron Pharmaceuticals Inc |
-7.94 (-0.69%) |
USD 127.14B |
| VRTX | Vertex Pharmaceuticals Inc |
-7.10 (-1.48%) |
USD 125.27B |
| ALNY | Alnylam Pharmaceuticals Inc |
-1.31 (-0.48%) |
USD 35.24B |
| ARGX | argenx NV ADR |
+6.84 (+1.31%) |
USD 32.19B |
| MRNA | Moderna Inc |
-2.13 (-2.96%) |
USD 26.25B |
| SMMT | Summit Therapeutics PLC |
-1.66 (-6.33%) |
USD 23.47B |
| BGNE | BeiGene Ltd |
-0.23 (-0.12%) |
USD 21.94B |
| BMRN | Biomarin Pharmaceutical Inc |
+0.59 (+0.84%) |
USD 16.16B |
| UTHR | United Therapeutics Corporatio.. |
-2.43 (-0.70%) |
USD 15.09B |
| PCVX | Vaxcyte Inc |
-0.21 (-0.18%) |
USD 14.27B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| ROYL:AU | BetaShares Global Royalti.. | 6.37 % | 0.00 % |
-0.02 (0%) |
N/A |
| ROYA | 4.80 % | 0.00 % |
N/A |
N/A | |
| FORH | Formidable ETF | 3.23 % | 0.00 % |
-0.12 (0%) |
USD 0.02B |
| IHE | iShares U.S. Pharmaceutic.. | 0.00 % | 0.42 % |
-0.02 (0%) |
N/A |
| Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 0.43% | 61% | D- | 49% | F | ||
| Dividend Return | 2.24% | 43% | F | 52% | F | ||
| Total Return | 2.67% | 63% | D | 51% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | 2.77% | 60% | D- | 48% | F | ||
| Dividend Return | 3.02% | 43% | F | 46% | F | ||
| Total Return | 5.79% | 61% | D- | 50% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -9.38% | 43% | F | 26% | F | ||
| Dividend Return | -7.99% | 46% | F | 27% | F | ||
| Total Return | 1.40% | 33% | F | 34% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 12.71% | 99% | N/A | 85% | B | ||
| Risk Adjusted Return | -62.84% | 22% | F | 15% | F | ||
| Market Capitalization | 16.45B | 99% | N/A | 95% | A | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company has under performed its peers on annual average total returns in the past 5 years.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median revenue growth in the previous 5 years compared to its sector
